Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
US10132810B2 · kind B2 · utility
3Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 27, 2013 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | Nov 27, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.